What is the FOURIER trial?
The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) is a trial that evaluated the PCSK9 inhibitor evolocumab among patients with ASCVD who met at least 1 major or 2 minor criteria. Recruitment was limited to patients who had LDL-C 70 mg/dL (1.8 mmol/L) (or non HDL-C 100 mg/dL (2.6 mmol/L)) on maximal statin ezetimibe.